Core Biogenesis Competitors and Similar CompaniesClear all
Core Biogenesis's competitors and similar companies include NextCure, Elicio Therapeutics, Cullgen and Ayala Pharmaceuticals.
 Core Biogenesis Core Biogenesis is a biotech company developing a production platform to express recombinant proteins from plants. |  NextCure NextCure is a biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs. |  Elicio Therapeutics Elicio Therapeutics (formerly known as Vedantra Pharmaceuticals) is an immuno-oncology company developing vaccines and immunotherapies for aggressive solid and hematologic cancers. |  Cullgen Cullgen is a biotech drug discovery company dedicated to the development of targeted protein degraders. |  Ayala Pharmaceuticals Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for cancers that are genetically defined. | |
Founding Date | Founding Date 2020 | Founding Date 2015 | Founding Date 2011 | Founding Date 2018 | Founding Date 2017 |
Type | Type Private | Type Public | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations Paris, FR HQ Illkirch Graffenstaden, FR | Locations Beltsville, US HQ | Locations Cambridge, US HQ | Locations San Diego, US HQ Shanghai, CN Tokyo, JP | Locations Wilmington, US HQ Rehovot, IL Wilmington, US |
Employees | Employees 293% decrease | Employees N/A | Employees 22 | Employees 4 | Employees 29 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 39.2 m | Valuation ($) 47.5 m | Valuation ($) N/A | Valuation ($) 7.4 m |
Financial | |||||
Net income | Net income N/A | Net income ($55.8m) (FY, 2025) | Net income ($39.6m) (FY, 2025) | Net income N/A | Net income ($38m) (FY, 2022) |
Funding | |||||
Latest funding round | Latest funding round $ 11m (about 4 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 16m (about 7 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 14.1m | Total funding raised $ 160m | Total funding raised $ 150.3m | Total funding raised $ 31m | Total funding raised $ 47m |
For sources of this data, please see the company profile
View Company Profiles
NextCure
HQ
Beltsville, US
NextCure is a biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs.
View companyElicio Therapeutics
HQ
Cambridge, US
Employees
22
Elicio Therapeutics (formerly known as Vedantra Pharmaceuticals) is an immuno-oncology company developing vaccines and immunotherapies for aggressive solid and hematologic cancers.
View companyCullgen
HQ
San Diego, US
Employees
4
Cullgen is a biotech drug discovery company dedicated to the development of targeted protein degraders.
View companyAyala Pharmaceuticals
HQ
Wilmington, US
Employees
29
Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for cancers that are genetically defined.
View company